LncRNA TLR8-AS1 promotes metastasis and chemoresistance of ovarian cancer through enhancing TLR8 mRNA stability
Authors:
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 526 (4) , 857-864
Abstract
No abstract availableKeywords
Funding Information
- Science and Technology Program of Fujian Province, China (2018Y2003)
This publication has 24 references indexed in Scilit:
- lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5Molecular Therapy, 2017
- Ovarian cancer stem cells more questions than answersSeminars in Cancer Biology, 2017
- Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNClinical Cancer Research, 2017
- Integrative Development of a TLR8 Agonist for Ovarian Cancer ChemoimmunotherapyClinical Cancer Research, 2017
- Long Noncoding RNA LINC00092 Acts in Cancer-Associated Fibroblasts to Drive Glycolysis and Progression of Ovarian CancerCancer Research, 2017
- A Phase I Dose-Finding Study of the Novel Toll-like Receptor 8 Agonist VTX-2337 in Adult Subjects with Advanced Solid Tumors or LymphomaClinical Cancer Research, 2014
- Interleukin-1 Receptor-associated Kinase-2 Genetic Variant rs708035 Increases NF-κB Activity through Promoting TRAF6 UbiquitinationJournal of Biological Chemistry, 2014
- Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistanceJournal of Clinical Investigation, 2010
- Efficacy assessment of sustained intraperitoneal paclitaxel therapy in a murine model of ovarian cancer using bioluminescent imagingBritish Journal of Cancer, 2008
- TLR7 and TLR8 as targets in cancer therapyOncogene, 2008